Neuroblastoma is a unique malignancy in infants often presenting with either localized or metastatic disease. The study was carried out to explore the risk stratification of the poor prognosis for patients underwent surgical treatment.
Introduction
Neuroblastoma is a heterogeneous tumor rising from neural crest progenitor cells, which appears as the most frequently diagnosed extra-cranial solid tumor in children, accounting for nearly 10% of all childhood cancers. [1] [2] [3] It is a unique malignancy in that infants often present with either localized or metastatic disease which can spontaneously regress without intervention while elder children can succumb to the disease after months to years of arduous therapy. [4, 5] There are studies showed that the over whole survival rates of patients with the most aggressive neuroblastoma are < 40%, even after intensive therapy. [6, 7] A lot of previous studies have investigated the NB as aspect of epidemiology, molecular mechanism, chemotherapy, radiotherapy and so on. [8, 9] Over the past several decades, the outcome for childhood cancer has improved dramatically. However, the longterm outcome of children with NB that are classified as high risk remains poor. [10, 11] The improved understanding of neuroblastoma biology and its impact on prognosis has relatively resulted in better tailoring of therapy. In clinical, the requirement for further surgical resection, chemotherapy, or radiotherapy is based upon a patient's risk stratification with general principles of therapy. [12] So far, several studies have published the potential risk factors which contributed to outcomes of NB patients. [13, 14] But as far as we know, it is the first study which specifically focus on risk factors for outcomes of the patients underwent surgical treatment.
Methods and materials

Ethical considerations
This retrospective study was approved by the ethics committee of Children hospital, Soochow University. We acquired all the informed consent from the enrolled patients before the study. All the methods in the research were performed in accordance with the relevant guidelines and regulations.
Subjects selected for the study
Around 60 patients diagnosed with neuroblastoma were primarily enrolled in the study from April 2008 to April 2016. Strict inclusion and exclusion criteria were adopted to address potential sources of bias. Inclusion criteria of the enrolled subjects have been described below: pathological results proved to be neuroblastoma; the survival condition of the enrolled patients could be identified; all the patients enrolled in the study underwent surgical treatment and/or chemotherapy; patients ranged from 0 to 18 months old; absence of metastases, and no previous chemotherapy. Exclusion criteria included patients received additional treatment before enrollment, incomplete data during follow-up. Clinical variables including International Neuroblastoma Staging System (INSS) stage, tumor histopathology, MYCN status, primary tumor sites and size, and type of tumor resection were collected and analyzed for all patients.
Treatment
The need for the preoperative chemotherapy was confirmed with the oncologists and surgeons based on the tumor size and sites and resectibility at presentation. Patients were offered chemotherapy if there were signs of organ dysfunction, life-threatening symptoms, or spinal cord compression. All the patients underwent surgical resection. The thoracic neuroblastomas were approached through a standard lateral thoracotomy. For cervical neuroblastomas, surgery was carried out with a transverse crease incision. Since most of the abdominal tumors are found in the upper abdomen, the thoracoabdominal approach was chosen in this situation. For patients underwent incomplete tumor resection, postoperative chemotherapy was performed.
Type of tumor resection
Complete excision was defined as excision of all visible tumor, including abnormal lymph nodes, which corresponds to INSS stage 1. Near-complete excision was considered as removal of the tumor with a minimal macroscopical residue, which related to INSS stage 2. Partial excision was defined as removal of the tumor with a macroscopic gross residue. This corresponds to INSS stage 3. Also partial excision is also related to the rare cases in which the tumor is resected completely, however the contralateral lymph nodes are infiltrated by the tumor.
Follow-up and grouping
All patients enrolled in the study were followed-up by outpatient service. All the patients received follow-up examinations every 3 months for 2 years after operation. After that patients received follow-up examinations twice a year for 3 to 5 years after operation. Lost follow-up was defined as losing contact with the medical staff more than 6 months during the follow-up period. All the enrolled patients were divided into good prognosis group and poor prognosis group. The outcomes include the state of disease evaluated based on the International Neuroblastoma Treatment Response Criterion (INRC): complete remission (CR) was defined as no residual tumor was found in CT, bone scan, bone marrow smear and physical examination for more than one month; partial remission (PR) was defined as the volume of the tumor is reduced by more than 50% for at least one month; tumor progression (TP) was defined as new metastatic lesion was found or the primary tumor becomes larger; patient death (PD) was defined as the enrolled died of the neuroblastoma during the follow-up period. [15] The good prognosis group consist of patients with the results of CR and PR, and the bad prognosis group consist of patients with the results of TP and PD. No potential confounders could be found in the present study.
Survival analyses
Event-free survival (EFS) was defined as time from diagnosis until time of first occurrence of relapse, secondary malignancy, death, or until time of last follow-up if none of these happened.
Univariate analyses using a log-rank test, at a 5% significance level and without adjustment for multiple testing, were performed to identify factors statistically significantly predictive of EFS to be carried forward into the survival regression.
Statistical analysis
All the statistical analyses were carried out by using SPSS 21.0 (SPSS, Chicago, IL). Data are presented as mean ± standard deviations (SD). Cox multifactor regression analysis was performed to identify factors independently associated with the prognosis of the neuroblastoma after surgical treatment. Survival curve was also applied to compare the survival rate between different groups. ROC (receiver operating characteristic) curve was constructed and the area under curve (AUC) was calculated to identify which parameter is most sensitive at predicting the recrudescence of the neuroblastoma after the surgical treatment. Cut point value was acquired by calculating the maximum value of sensitivity plus specificity. Tests were performed using 2-tailed and P < .05 was considered significant difference.
Results
Patients characteristics
The average follow-up period was 40.2 ± 8.6 months. Of all enrolled patients, 32 were diagnosed before the age of 12 months. Thirty-six patients presented with abdominal primary and 24 patients were diagnosed with a head or neck primary. With regard to INSS stage system, 22 patients were found in stage 1, 20 patients in stage 2 and 18 patients in stage 3. Computed tomography (CT) defined the tumor location at the thoracic (n = 21), cervical (n = 12), and abdominal (n = 27). The histology and MYCN status were also determined in each patient. The characteristics of these patients are given in Table 1 . 
Type of tumor resection
The type of excision varied significantly according to tumor location and size. There are 12 cases of cervical neuroblastoma extending to the thoracic inlet. They all underwent complete excision using a cervical approach. Sixteen of the twenty-one thoracic neuroblastomas were completely or near-completely resected via thoracotomy. The remaining 6 patients with encasement of vessels received partial resection. For 8 out of 27 abdominal neuroblastomas, the initial surgical approach was limited to partial resection. Complete tumor resection was achieved in 12 patients and near-complete tumor resection in 7 patients. The type of surgery used in each case is presented in Table 2 .
Outcomes
Among 60 patients, CR was achieved in 35 patients, while PR was 14 subjects. Good prognosis group included the patients with the CR and PR results. Poor prognosis group included subjects (Fig. 1) .
Survival analysis
Consistent with prior studies, age was a key factor which determined EFS. As Figure 2 showed, patients under 12 months had higher EFS rates than that of patients more than 12 months (P < .01). Figure 3 showed the Kaplan-Meier survival curves for patients with different histological types. Patients with neuroblastoma had worse EFS, with recurrence occurring earlier than patients with ganglioneuroblastoma. EFS declined precipitously during first year of follow-up, subsequent a slowing in the decline after one year of follow-up. In link with previous results, MYCN status was another prognostic factors associated with patients EFS periods after primary surgery. Amplified MYCN status group showed an early decline over the first 1.5 years with a more gradual decline after 2 years of follow-up. The non-amplified MYCN status group showed a higher EFS than the amplified MYCN group (P < .01) (Fig. 4) . Table 2 The type of tumor resection and chemotherapy. Table 3 Univariate and multivariate analysis of poor prognosis (n = 60).
Patients (n = 60)
Factor
Poor prognosis group (n = 11) 
Discussion
Previous studies have demonstrated that the outcome of recurrent high-risk neuroblastoma was much worse than those of primary intermediate-risk tumors. [16, 17] The role of surgery in the treatment of neuroblastoma is no doubt the mainstay of therapy for the majority of patients with localized neuroblastoma. [18, 19] However, there is no convincing evidence which could predicts the outcome of neuroblastoma patients underwent tumor resection. Given that tumor resection may be acceptable for most low-and intermediate-risk patients, the need to determine prognostic factors after surgical treatment has become increasingly apparent. In our study, the prognostic factors of 6 variables were analyzed, and EFS was chosen as the endpoint. Our data showed that 3 of 6 variables were highly statistically significant and also considered clinically relevant.
Survival analysis confirmed that the predictive ability of age was continuous in nature for neuroblastoma. However, inconsistent with some previous publications, our study found that the optimal age cut-off is 12 months. While London et al [20] reported statistical support existed for an age cut-off of 460 days. This discrepancy might reflect the different inclusion criteria of patients, with previous article include patients under INSS stage 4 and therefore postponing the cut-off age. Susan et al [21] support for an optimal "cut-off" between 15 and 19 months. They found that children younger than 18 months had EFS and OS rates of 63% ± 2% and 68% ± 2%, respectively. Children of 18 months of age or older had EFS and OS rates of 23% ± 1% and 31% ± 1%, respectively. Besides, they also analyzed the EFS rates for patients in stage 4 tumors younger than 12 months and found there was no statistically different between patients of 12 months or older and patients younger than 12 months. In addition, they also claimed that for patients with diploid, stage M, MYCN nonamplified tumors, the more conservative age cut-off of 12 months might be more acceptable. Our results elucidated that patients with age under 12 months had a significantly higher EFS rate than those more than 12 months. Taken together, INSS stage should be taken into consideration when select the optimal cut-off age. Tumor histology is another well-established prognostic variable in neuroblastoma. [22, 23] Our data were in accordance with previous studies showing the better prognosis in ganglioneuroblastoma than in neuroblastoma. [23] We found that a better EFS rate in patients with ganglioneuroblastoma than that in neuroblastoma. In the spectrum of differentiation of neuroblastic tumors, ganglioneuroblastoma, nodular subtype, occupies a unique position. The International Neuroblastoma Pathology Classification (INPC) defines it as a stroma-dominant or stromarich tumor, surrounding by one or more macroscopic nodules of stroma-poor neuroblastoma. [24] Angelini et al [25] found that patients with ganglioneuroblastoma were older, a larger proportion had unfavorable INPC pathology, and rarely had MYCN amplified status when compared with those with neuroblastoma. However, they determined that the 5-year EFS in ganglioneuroblastoma was 70% ± 1% (vs 81.8 ± 1%), a slight lower compared with our results. This discrepancy of EFS rates can be explained by different selected patients. In Angelini's study, they included patients in INSS stage 4, which have worse EFS rate. However, even in this situation, this 5-year EFS rate was higher than patients with neuroblastoma in our study (70% vs 54.5%).
MYCN status played an important role in predicting prognosis of neuroblastoma patients. Amplification of MYCN was found in 25% of neuroblastoma patients and regarded as a biomarker for poor prognosis. Currently, MYCN amplification remains the best-characterized genetic marker of risk in neuroblastoma. [26] Previous study showed MYCN status was the most powerful prognostic factor within non-stage 4 neuroblastoma patients. [21] They found that patients with MYCN non-amplified status had EFS of 87% ± 1% and OS of 95% ± 1%, and 46% ± 4% and 53% ± 4% for patients with MYCN-amplified status. Canete et al [27] enrolled 46 infants with MYCN amplification and found 2-year EFS was 29%. Many studies also reported other genetic markers such as DNA ploidy, neurotrophin receptors could be used as prognostic factors. [28] [29] [30] Unlike other studies, we decided to only consider MYCN status because this formed a clear biologic subgroup with a well-known and well-described aggressiveness.
Neuroblastoma is a heterogeneous malignancy with prognosis ranging from near uniform survival to high risk for fatal demise. Neuroblastoma serves as a paradigm for the prognostic utility of biologic and clinical data and the potential to tailor therapy for patient cohorts at low, intermediate, and high risk for recurrence. [31] Studies have demonstrated that patients with low risk disease can be treated with surgery alone and supported a role for >90% resection of the primary tumor in high-risk patients. [32] Although overall survival is excellent for patients who have low-and intermediate-risk neuroblastoma with a general trend toward minimization of therapy, mortality rate is still high for high-risk patients. [33] Thus it is of importance to identify the characteristics which could predict the outcomes of patients. In our study, we found that surgical treatment to patients with localized neuroblastoma has good outcomes. Besides, our results also elucidated that several variables including younger age, ganglioneuroblastoma and MYCN nonamplified status correlated with good prognosis after surgery. We consider these prognostic factors will help in predicting outcomes of surgical treatment in clinical practice in the future.
One limitations of this study was relatively small sample groups, larger group studies need to be performed to firmly establish the conclusions; the second limitation of the study is the retrospective study, as in so many similar published study, may induce selection bias; thirdly, the limited number of enrolled patients may result in the selective bias. From our series, we found that surgical treatment for patients with localized neuroblastoma had favorable outcomes. Besides, our results also elucidated that several variables including younger age, ganglioneuroblastoma and MYCN non-amplified status correlated with good prognosis after surgery. We hope that these prognostic factors will help in predicting outcomes of surgical treatment in the future.
Conclusion
In our study, we identified a series of prognostic factors including age, histology and MYCN status predicting the prognosis of neuroblastoma patients after surgical treatment.
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